Invenis Biotherapies
deck
Invenis Biotherapies
Description
Invenis is a preclinical stage biotech developing regenerative cell-free therapies derived from the body's own physiological healing system - the human blood platelets - to treat patients suffering from severely debilitating diseases associated with neurodegeneration, for which no effective treatment exists.
Our biomedicine is a proprietary, pathogen-free platelet secretome (PS) produced from GMP-grade platelet concentrates supplied by blood centers (EFS, Red Cross…) from healthy donors. This PS is composed of a plethora of trophic factors (growth factors, antioxidant, anti-inflammatory molecules…) which are known to promote the survival, repair and regeneration of neurons.
In terms of MoA, our biotherapy is very similar to cell therapy in that the transplanted cells do not replace damaged cells, but rather secrete trophic factors into the extracellular environment, activating intracellular signaling pathways that promote neuroprotection. However, as a cell-free therapy, it does not have the disadvantages associated with cell therapy (immunogenicity, tumorigenicity, heterogeneity….)
The therapeutic potential of our PS has been validated in several in vitro and in vivo models of neurodegenerative diseases: Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS) and Traumatic Brain injury (TBI). In particular, in ALS models, our PS increases the lifespan of SOD1G86R mice compared to Riluzole, the ALS gold standard treatment, and restores the neuromuscular endplates of gastrocnemius muscle in TDP-43Q331K mice.
Our roadmap over the next 3 years is to complete the IND-enabling studies to bring our lead ALS program into the clinic in the 2nd quarter of 2027.
Our Documents
